Choroidal Neovascularizatio
n Drug Market
Choroidal Neovascularization Drug Market Scope:
Industry Analysis, Market Size, Growth, Trends Till
2031
Request Sample Report
Choroidal Neovascularization Drug Market Size and Growth
The Choroidal Neovascularization Drug market is experiencing significant growth, driven by increasing prevalence of retinal disorders and advancements in therapeutic options. The market size was valued at approximately $5.4 billion in 2022 and is projected to expand further, highlighting the demand for innovative treatments and enhanced patient outcomes in ocular health. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Cellphire, Inc.
◍ Chrysalis BioTherapeutics, Inc.
◍ Cleveland BioLabs, Inc.
◍ Cumberland Pharmaceuticals, Inc.
◍ Diffusion Pharmaceuticals Inc.
◍ Eli Lilly and Company
◍ GNI Group Ltd.
◍ Humanetics Corporation
◍ INSYS Therapeutics, Inc.
◍ Meabco A/S
◍ Neumedicines Inc.
◍ Onconova Therapeutics, Inc.
◍ PharmaIN Corporation
◍ Pluristem Therapeutics Inc.
◍ ProCertus BioPharm Inc.
◍ RDD Pharma Ltd.
◍ RedHill Biopharma Ltd.
The Choroidal Neovascularization Drug Market features companies like Eli Lilly, which offers anti-VEGF therapies, and RedHill Biopharma, focusing on innovative treatments. Others like Onconova Therapeutics and Soligenix contribute through research and development. These companies advance the market through innovative therapies and collaborative efforts, enhancing treatment options for patients.
Sales Revenue Figures:
- Eli Lilly: Approx. $21 billion
- RedHill Biopharma: Approx. $40 million
- Cumberland Pharmaceuticals: Approx. $150 million
◍ RxBio, Inc.
Request Sample Report
Market Segmentation
By Application
Clinic
Hospital
Others
Request Sample Report
By Product
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
Market Growth
Request Sample Report
$ X Billion USD
